What is it about?
Acquired JAK2 mutation has an important role on myeloproliferative neoplasms (MPNs), which is found in as high as 95% of patients with polycythemia vera, the commonest example of MPNs. Detection of this mutations varies according to the method used, real-time qPCR being the most sensitive of all and could detect tiny percentage of mutated cell population. Impact of this mutation on clinical and hematological parameters of MPN patients is studied here.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This study uses a highly sensitive method of detecting JAK2 mutation, namely real-time qPCR and have set a new cut-off value for clinically significant JAK2 allelic burden (ratio of mutated to non-mutated cells) among MPN cases.
Perspectives
Despite the low number of enrolled cases, this study confirmed what was found in literature and established a new cut-off value of JAK2 allelic burden to be considered clinically significant.
Prof. Bassam Musa Al-Musawi
College of Medicine, University of Baghdad
Read the Original
This page is a summary of: The impact of JAK2V617F allelic burden on clinical and laboratory parameters in patients with myeloproliferative neoplasms, January 2020, Africa Health Research Organization,
DOI: 10.36295/asro.2020.231366.
You can read the full text:
Resources
Contributors
The following have contributed to this page
